Dulac Edward J III
EVP, Chief Financial Officer
Dulac Edward J III has filed 4 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2026. 4 of those filings fall inside the rolling window. Most recent filing: Jul 24, 2026.
On the most recent filing, Dulac Edward J III is listed as EVP, Chief Financial Officer at Intellia Therapeutics, Inc. Inside the rolling window, Dulac Edward J III reported no open-market purchases and 3 open-market sales totaling $234K in NTLA. The largest disclosed transaction in the window is a sale of 8,111 NTLA shares on Jul 22, 2026, worth $91K.
Companies traded
Other insiders at NTLA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$234K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Dulac Edward J III made?
Dulac Edward J III has filed 4 SEC Form 4 filings (4 transaction rows) across 1 company since 2026.
Which companies does Dulac Edward J III trade?
Dulac Edward J III has filed SEC Form 4 disclosures for 1 company, including NTLA.
When was Dulac Edward J III's most recent SEC Form 4 filing?
Dulac Edward J III's most recent SEC Form 4 filing on Tracefour is dated Jul 24, 2026.
What is Dulac Edward J III's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Dulac Edward J III is listed as EVP, Chief Financial Officer.
What is Dulac Edward J III's total buy and sell value in the current window?
Inside the rolling retention window, Dulac Edward J III bought $0 and sold $234K based on SEC Form 4 filings.
What was Dulac Edward J III's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 8,111 NTLA shares on 2026-07-22, worth $91K, per SEC Form 4 filings.